The role of RNA editing enzyme ADAR1 in human disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Adenosine deaminase acting on RNA (ADAR) catalyzes the posttranscriptional conversion of adenosine to inosine in double‐stranded RNA (dsRNA), which can lead to the creation of missense mutations in coding sequences. Recent studies show that editing‐dependent functions of ADAR1 protect dsRNA from dsRNA‐sensing molecules and inhibit innate immunity and the interferon‐mediated response. Deficiency in these ADAR1 functions underlie the pathogenesis of autoinflammatory diseases such as the type I interferonopathies Aicardi‐Goutieres syndrome and dyschromatosis symmetrica hereditaria. ADAR1‐mediated editing of endogenous coding and noncoding RNA as well as ADAR1 editing‐independent interactions with DICER can also have oncogenic or tumor suppressive effects that affect tumor proliferation, invasion, and response to immunotherapy. The combination of proviral and antiviral roles played by ADAR1 in repressing the interferon response and editing viral RNAs alters viral morphogenesis and cell susceptibility to infection. This review analyzes the structure and function of ADAR1 with a focus on its position in human disease pathways and the mechanisms of its disease‐associated effects. This article is categorized under: RNA in Disease and Development > RNA in Disease RNA Processing > RNA Editing and Modification RNA Interactions with Proteins and Other Molecules > Protein‐RNA Interactions: Functional Implications
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 1×
“Therefore, EMT leads to metastatic tumors (Lamouille et al., 2014).”
A-to-I editing of coding and non-coding RNAs by ADARs
Nishikura, K. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.4 · Cited by 1,041
Self-citationAicardi–Goutières syndrome and the type I interferonopathies
Crow, Y. J., & Manel, N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3850 · Cited by 925 · cited 1×
“There are currently seven genes (TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, IFIH1) confirmed to be associated with AGS, and mutations in any of them can cause the syndrome (Crow & Manel, 2015).”
BackgroundMutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature
Rice, G. I., Kasher, P. R., Forte, G. M. A., Mannion, N. M., Greenwood, S. M., Szynkiewicz, M., Dickerson, J. E., Bhaskar, S. S., Zampini, M., Briggs, T. A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2414 · Cited by 923
The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers
Han, L., Diao, L., Yu, S., Xu, X., Li, J., Zhang, R., Yang, Y., Werner, H. M. J., Eterovic, A. K., Yuan, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.013 · Cited by 542 · cited 2×
“Analysis of the cancer genomic landscape revealed that across 17 cancer types, altered A-to-I editing events in tumor samples correlated best with the global editing of ADAR1, confirming its important role in cancer (Han et al., 2015).”
BackgroundHuman ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown
Chung, H., Calis, J. J. A., Wu, X., Sun, T., Yu, Y., Sarbanes, S. L., Dao Thi, V. L., Shilvock, A. R., Hoffmann, H.-H., Rosenberg, B. R., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.038 · Cited by 538 · cited 1×
“Levels of phosphorylated PKR in IFN-stimulated ADAR1-knockout cells were reduced upon the addition of a transcription inhibitor, showing that PKR activation was being triggered by endogenous RNA transcribed de novo and suggesting that ADAR1 works to mark such endogenous RNA as self (Chung et al., 2018).”
BackgroundBreaching Self-Tolerance to Alu Duplex RNA Underlies MDA5-Mediated Inflammation
Ahmad, S., Mu, X., Yang, F., Greenwald, E., Park, J. W., Jacob, E., Zhang, C.-Z., & Hur, S. (2018) · Cell · doi:10.1016/j.cell.2017.12.016 · Cited by 449 · cited 1×
“Alu dsRNAs were also less protected from MDA5 in ADAR1-knockout cells (Ahmad et al., 2018).”
BackgroundRodero, M. P., & Crow, Y. J. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20161596 · Cited by 433
Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity
Crow, Y. J., & Rehwinkel, J. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp293 · Cited by 289 · cited 1×
“Unlike congenital infections, the perturbation in interferon homeostasis is triggered by endogenous nucleic acids (Crow & Rehwinkel, 2009).”
Background
Cited by
Pattern recognition receptors: function, regulation and therapeutic potential
Chen, R., Zou, J., Chen, J., Zhong, X., Kang, R., & Tang, D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02264-1 · Cited by 301
Biochemical profiling and structural basis of ADAR1-mediated RNA editing
Deng, X., Sun, L., Zhang, M., Basavaraj, R., Wang, J., Weng, Y.-L., & Gao, Y. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.02.017 · Cited by 19
Leukodystrophy imaging: Insights for diagnostic dilemmas.
Thakkar, R. N., Patel, D., Kioutchoukova, I. P., Al-Bahou, R., Reddy, P., Foster, D. T., & Lucke-Wold, B. (2024) · Medical Sciences · doi:10.3390/medsci12010007 · Cited by 17
ADBP-1 regulates ADR-2 nuclear localization to control editing substrate selection
Eliad, B., Schneider, N., Ben-Naim Zgayer, O., Amichan, Y., Glaser, F., Erdmann, E. A., Rajendren, S., Hundley, H. A., & Lamm, A. T. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae641 · Cited by 7
Metadata
- Authors
- Song, B., Shiromoto, Y., Minakuchi, M., & Nishikura, K.
- Venue
- WIREs RNA
- Publisher
- Wiley
- Published
- 2021-06-08
- Volume
- 13
- Issue
- 1
- Pages
- e1665-e1665
- ISSN
- 1757-7004 (ISSN-L)
- 1757-7012
- OpenAlex
- W3170636902
- Cited by
- 142
- References
- 9
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.